Skip to main content
Menu
US
KRAS 1920x640
Whitepaper

Exploring current and future approaches for targeting KRAS

Get the latest insights on KRAS and see how it has switched from being an undruggable to a druggable cancer target.

In this white paper, find out more about:

  • The structure and function of the RAS protein superfamily
  • The role and consequences of KRAS gene activation
  • How renowned companies are targeting KRAS in cancer therapies and what the current challenges in developing KRAS-targeted therapeutics are
  • How to identify novel KRAS inhibitors and how to characterize downstream KRAS signaling with Alpha Surefire® Ultra and HTRF technologies
To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Exploring current and future approaches for targeting KRAS